Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF2-Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 May 2018
At a glance
- Drugs PT 2385 (Primary)
- Indications Glioblastoma
- Focus Pharmacogenomic; Therapeutic Use
- 11 May 2018 Planned primary completion date changed from 31 May 2018 to 31 Dec 2018.
- 11 May 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2017 Status changed from not yet recruiting to recruiting.